MT1 antibody (3rd Intracellular Loop)

Catalog No. ABIN7885142

The Rabbit Polyclonal anti-MT1 antibody (ABIN7885142) specifically detects MT1 in WB, IHC, IC and IF. The antibody is reactive with Rat and Mouse samples.

Quick Overview for MT1 antibody (3rd Intracellular Loop) (ABIN7885142)

Target: MT1 (Metallothionein 1 (MT1))

Reactivity: Rat, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This MT1 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunochromatography (IC), Immunofluorescence (IF)

Grade: Carrier-free

Product Details anti-MT1 Antibody

Binding Specificity: 3rd Intracellular Loop, AA 223-236

Purpose: A Rabbit Polyclonal Antibody to Melatonin Receptor Type 1A

Predicted Reactivity: Rat,human - 13,14 amino acid residues identical

Purification: Affinity purified on immobilized antigen.

Immunogen: (C)RVKPDNKPKLKPQD, corresponding to amino acid residues 223-236 of mouse MTNR1A

Isotype: IgG

Application Details

Application Notes:

WB: 1:200

FC: The optimal concentration should be determined by the user

ICC: The optimal concentration should be determined by the user

IHC: The optimal concentration should be determined by the user

IP: The optimal concentration should be determined by the user

Comment:

Negative Control: (ABIN7235936)

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: 0.2 mL double distilled water (DDW)

Concentration: 1 mg/mL

Buffer: PBS pH 7.4

Preservative: Without preservative

Storage: -20 °C

Storage Comment: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Target Details for MT1

Target: MT1 (Metallothionein 1 (MT1))

Alternative Name: MT1

Background:

Synonyms: MT1, Mel1a receptor, Mel-1A-R

Description: Melatonin (N-acetyl-5-methoxytryptamine) is a product of tryptophan metabolism. It is synthesized in the pineal gland and is secreted to control the circadian rhythm1-3. Melatonin is also synthesized in the gastrointestinal tract, retina, skin and other tissues where it acts in a autocrine or paracrine manner. The role of melatonin in these tissues is independent of its role in the circadian rhythm, where it plays a role in energy metabolism, physiological growth, differentiation and responsiveness in stress stimuli1. The pleiotropic effects of melatonin have given rise to various therapeutic possibilities for this molecule. For example, anti-stress, sexual dysfunction, obesity, gallbladder stones1,4. To date, the only therapeutic uses for melatonin remain to treat sleep disorders, depression, migraine and headaches1.Melatonin exerts its effects through two G-protein coupled receptors (GPCRs), melatonin receptor type 1 and melatonin receptor type 2 (MT1 and MT2). Like all GPCRs, they have seven transmembrane domains and extracellular N-terminal and cytoplasmic C-terminal tails. The binding of melatonin to either receptor activates Gi, thereby activating PLC, thus increasing intracellular Ca2+ levels. Both receptors structurally bind melatonin in the same manner, although MT2 displays a much higher affinity for the hormone. Just like melatonin levels are detected in many tissues, the expression patterns of the two receptors are also quite broad. For example, MT1 is detected in the brain, retina and kidneys and MT2 is expressed in brain and in the retina1.MT1 is involved in sleep regulation and might also have effects on peripheral vasoconstriction. MT2 may play an important physiological role in the retina and might regulate body temperature1.

Gene ID: 17773

UniProt: Q61184

Pathways: Transition Metal Ion Homeostasis